Sutro Biopharma Inc

NASDAQ:STRO   3:46:55 PM EDT
18.35
-1.05 (-5.41%)
Products, Regulatory

Sutro Biopharma Announces Encouraging Interim Data On Stro-002 Phase 1 Dose-Escalation Study For Patients With Ovarian Cancer

Published: 12/03/2020 21:51 GMT
Sutro Biopharma Inc (STRO) - Sutro Biopharma Announces Encouraging Interim Data on Stro-002 Phase 1 Dose-escalation Study for Patients With Ovarian Cancer.
Sutro Biopharma Inc - Responses Observed in 32% of Evaluable Patients Treated at Clinically Active Dose Levels-including 1 Cr, 3 Cprs and 6 Uprs.
Sutro Biopharma Inc - Stro-002 Continues to Be Well-tolerated.
Sutro Biopharma Inc - 86% of All Treatment-emergent Adverse Events of Atro-002 Were Grade 1 Or 2.